These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38543741)

  • 21. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C reinfection in former and active injecting drug users in Belgium.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Verrando R; de Galocsy C; Van Steenkiste C; Nevens F; Midgard H; Dalgard O; Robaeys G
    Harm Reduct J; 2021 Oct; 18(1):102. PubMed ID: 34641896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.
    Huang P; Wang Y; Yue M; Ge Z; Xia X; Jeyarajan AJ; Holmes JA; Yu R; Zhu C; Yang S; Lin W; Chung RT
    Liver Int; 2021 Oct; 41(10):2341-2357. PubMed ID: 34051040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
    PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland.
    Falcato L; Bernardini C; Bruggmann P
    Int J Drug Policy; 2021 Oct; 96():103434. PubMed ID: 34511311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
    Yazdani K; Dolguikh K; Zhang W; Shayegi-Nik S; Ly J; Cooper S; Trigg J; Bartlett S; Barrios R; Montaner JSG; Salters K
    PLoS One; 2022; 17(3):e0265811. PubMed ID: 35320316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence.
    Steininger L; Chromy D; Bauer D; Simbrunner B; Binter T; Schwabl P; Schmidbauer C; Trauner M; Gschwantler M; Mandorfer M; Reiberger T
    Wien Klin Wochenschr; 2021 May; 133(9-10):452-460. PubMed ID: 33351152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C Virus Reinfection Among People Who Inject Drugs: Long-Term Follow-Up of the HERO Study.
    Litwin AH; Tsui JI; Heo M; Mehta SH; Taylor LE; Lum PJ; Feinberg J; Kim AY; Norton BL; Pericot-Valverde I; Arnsten J; Meissner P; Karasz A; McKee MD; Ward JW; Johnson N; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Carty J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Groome M; Davies S; Costello K; Page K;
    JAMA Netw Open; 2024 Aug; 7(8):e2430024. PubMed ID: 39186268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HCV Cascade of Care in HIV/HCV Co-Infected Individuals: Missed Opportunities for Micro-Elimination.
    Thomadakis C; Basoulis D; Tsachouridou O; Protopapas K; Paparizos V; Astriti M; Chini M; Chrysos G; Marangos M; Panagopoulos P; Kofteridis D; Sambatakou H; Mastrogianni E; Panatzis N; Pechlivanidou E; Psichοgiou M; Touloumi G;
    Viruses; 2024 May; 16(6):. PubMed ID: 38932178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
    Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
    Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.
    Lodi S; Klein M; Rauch A; Epstein R; Wittkop L; Logan R; Rentsch CT; Justice AC; Touloumi G; Berenguer J; Jarrin I; Egger M; Puoti M; D'Arminio Monforte A; Gill J; Salmon Ceron D; van Sighem A; Linas B; van der Valk M; Hernán MA;
    J Int AIDS Soc; 2022 Dec; 25(12):e26048. PubMed ID: 36562643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated.
    Morris MD; Mirzazadeh A; Evans JL; Briceno A; Coffin P; Hahn JA; Page KA
    Drug Alcohol Depend; 2019 May; 198():133-135. PubMed ID: 30921649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
    J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
    Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
    World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.
    Grady BP; Vanhommerig JW; Schinkel J; Weegink CJ; Bruisten SM; Lindenburg CE; Prins M
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1302-7. PubMed ID: 22825643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.